Almost 1 in 8 people with symptoms turned away from sexual health clinics in SE London: 40% are under 25 and 6% under 18 years old
1 May 2018. Related: Conference reports, Treatment access, Women's health, Pregnancy, HIV prevention and transmission.
Treatment access
Drug cost savings from routine use of generic ARVs: safety and efficacy in practice
1 May 2018. Related: Conference reports, Antiretrovirals, Treatment access.
Continued demands to stop NHS Digital linking medical records to deportation services
1 May 2018. Related: Treatment access, Other news.
FDA grants tentative approval to first DTG/FTC/TAF FDC
23 February 2018. Related: Antiretrovirals, Treatment access.
Universal ART on diagnosis: approved by NHS England
23 February 2018. Related: Treatment access.
75% of WHO essential medicines could be cheaper: UK and South Africa both overpay
9 February 2018. Related: Treatment access.
London clinic to prescribe generic PrEP privately at £55 for 30 tablets
9 February 2018. Related: Treatment access, HIV prevention and transmission.
MSF secures generic hepatitis C treatment at $120 per course
28 November 2017. Related: Treatment access, Hepatitis coinfection, Other news.
Generic dolutegravir-based FDCs at US $75 a year for low- and middle-income countries
1 October 2017. Related: Treatment access.
UK donates well to the Global Fund, but slashed bilateral aid for HIV
1 October 2017. Related: Treatment access.
Dozens of countries left out of new PEPFAR strategy, threatening the global AIDS response
1 October 2017. Related: Treatment access.
NHS access to PrEP in the UK: country update
1 October 2017. Related: Treatment access, HIV prevention and transmission.
Generic PrEP in France and Scotland challenges access across the UK
1 October 2017. Related: Treatment access, HIV prevention and transmission.
Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study
10 August 2017. Related: Conference reports, Antiretrovirals, Treatment strategies, Treatment access.
Swaziland nearly halves HIV incidence in five years
10 August 2017. Related: Conference reports, Treatment access.
First dolutegravir-based generic FDC gets FDA tentative approval
10 August 2017. Related: Antiretrovirals, Treatment access.
WHO adds dolutegravir and PrEP to updated Essential Medicine List
26 June 2017. Related: Treatment access.
Cochrane review of HCV treatment misses real issues of access to care
26 June 2017. Related: Treatment access, Hepatitis coinfection.
PrEP approved in Scotland but not in Wales
24 April 2017. Related: Treatment access, HIV prevention and transmission.
Sutezolid added to MPP as potential TB drug
27 February 2017. Related: Treatment access.
AT LAST: Gay men and transgender people in England get vaccine to prevent genital warts and anal cancer – impressive pilot results
27 February 2017. Related: Treatment access, Coinfections and complications, Other news.
1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs
29 November 2016. Related: Conference reports, Treatment access.
CHAI’s ARV market report shows more people than ever on ART in 2015 – and on better ART: but still some way to go
29 November 2016. Related: Treatment access.
New online database for patent expiry dates in low- and middle-income countries
29 November 2016. Related: Treatment access, On the web.
Global Fund is $2.6 billion short for 2017-2019: only $10.3 rather than 12.9 billion is available
29 November 2016. Related: Treatment access.
Large disparities in costs of antiretrovirals between low- and middle-income countries
1 October 2016. Related: Conference reports, Antiretrovirals, Treatment access.
First generic version of dolutegravir approved by the FDA
1 October 2016. Related: Treatment access.
Brazil to start using dolutegravir first-line in its national programme
1 October 2016. Related: Treatment access.
Global Fund to reach US $13 billion target for 2017-2019: UK pledges up to $1.3 billion
1 October 2016. Related: Treatment access.
Sub-Saharan African countries moving quickly to recommend “Treat All”
1 August 2016. Related: Conference reports, Treatment access, Guidelines.
NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos
2 June 2016. Related: Treatment alerts, Treatment access, HIV prevention and transmission.
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.
Timeline for access to generic dolutegravir: what still needs to be done
1 June 2016. Related: Treatment access.
Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART
1 June 2016. Related: Treatment access.
South Africa takes bold step to provide HIV treatment for all
1 June 2016. Related: Treatment access.
New antiretrovirals could mean savings up to US $3 billion by 2025
22 March 2016. Related: Conference reports, Treatment access.
Countries with lower HIV prevalence have lower ART coverage
22 March 2016. Related: Conference reports, Antiretrovirals, Treatment access.
Community oppose dolutegravir and cabotegravir patents in India
22 March 2016. Related: Treatment access.
MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years
22 March 2016. Related: Treatment access.
Global Fund provides Uganda with a year of drugs to meet shortages
22 March 2016. Related: Treatment access.
Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives
22 March 2016. Related: Treatment access.
Mbeki shows no remorse for role in AIDS deaths
22 March 2016. Related: Treatment access.
Treatment as Prevention (TasP) in the UK supports access to ART at any CD4 count
1 February 2016. Related: Treatment access.
WHO 2015 guidelines: newly recommended generic ART products on the way for adults
1 February 2016. Related: Treatment access.
Better generic ART for low and middle income countries: dolutegravir at US $44 a year
1 February 2016. Related: Treatment access.
When Global Fund support ends: Sustainability lessons from transitions in Costa Rica, Fiji, Romania, and Bulgaria
1 February 2016. Related: Treatment access.
Price of MDR TB drugs could be greatly reduced with competitive generic manufacture
1 December 2015. Related: Conference reports, Treatment access, TB coinfection.
Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23
1 December 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
CHAI’s ARV market report predicts that new drugs and formulations will drive the next major drop in treatment costs
1 December 2015. Related: Treatment access.
New trade agreements threaten treatment access in Asia
1 December 2015. Related: Treatment access.
Why the 5000% price hike for pyrimethamine in the US is relevant in the UK
1 October 2015. Related: Treatment access.
Proposed TTIP trade agreement in Europe: Report shows European Commission’s access to medicines commitments are ‘empty gestures’
1 October 2015. Related: Treatment access.
Australian doctors advice for buying generic sofosbuvir for HepC
1 October 2015. Related: Treatment access, Hepatitis coinfection.
“We will win or lose the fight against AIDS in next five years”: UNAIDS and Lancet commission report
1 August 2015. Related: Treatment access, On the web.
The option for same day antiretroviral therapy on diagnosis: the future model for HIV care
1 August 2015. Related: Conference reports, Treatment strategies, Treatment access, Treatment advocacy, Other news.
New directions in the 2015 WHO ART guidelines
1 August 2015. Related: Conference reports, Treatment access, Guidelines.
Large variation across countries in meeting UNAIDS 90-90-90 targets
1 August 2015. Related: Conference reports, Treatment access.
Generic dolutegravir submitted to FDA for tentative approval
1 June 2015. Related: Antiretrovirals, Treatment access.
Lopinavir/ritonavir pellets tentatively approved by the FDA
1 June 2015. Related: Treatment access.
Sofosbuvir access: new patent challenges to sofosbuvir
1 June 2015. Related: Treatment access, Hepatitis coinfection.
Hepatitis C drug access: Europe is the new Africa
29 January 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
Morocco’s acceptance of EU patent law threatens millions of lives
29 January 2015. Related: Treatment access.
Global Fund releases end-2104 numbers
29 January 2015. Related: Treatment access.
India rejects Gilead’s patent application for sofosbuvir
29 January 2015. Related: Treatment access, Hepatitis coinfection.
Savings to the NHS predicted from switching to generic antiretrovirals
1 December 2014. Related: Conference reports, Antiretrovirals, Treatment access.